Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. | About two and a half years after originating the role ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.